Chidamide Combined With Toripalimab in Sarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

January 19, 2020

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2024

Conditions
Sarcoma
Interventions
DRUG

chidamide and toripalimab

"The eligible patients with advanced soft tissue sarcoma were treated with chidamide combined with toripalimb. Chidamide 30mg orally twice a week;~Toripalimab 240 mg (fixed dose) every three weeks.~Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment."

Trial Locations (1)

510000

RECRUITING

Sun Yat-Sen Univerisity, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER